Fulcrum Therapeutics, Inc. (FULC) › Operating IncomeFulcrum Therapeutics, Inc. (FULC) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2018: -$33.50M2019: -$84.22M2020: -$71.61M2021: -$81.05M2022: -$112.56M2023: -$110.66M2024: -$21.90M2025: -$84.77M-$84.77M2018Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$84.77M-287.1%2024-$21.90M+80.2%2023-$110.66M+1.7%2022-$112.56M-38.9%2021-$81.05M-13.2%2020-$71.61M+15.0%2019-$84.22M-151.4%2018-$33.50M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share